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ABSTRACT: Drug-resistance acquisition through kinase gate-keeper
mutations is a major hurdle in the clinic. Here, we determined the ﬁrst
crystal structures of the human FGFR4 kinase domain (FGFR4K) alone
and complexed with ponatinib, a promiscuous type-2 (DFG-out) kinase
inhibitor, and an oncogenic FGFR4K harboring the V550L gate-keeper
mutation bound to FIIN-2, a new type-1 irreversible inhibitor.
Remarkably, like ponatinib, FIIN-2 also binds in the DFG-out mode
despite lacking a functional group necessary to occupy the pocket vacated
upon the DFG-out ﬂip. Structural analysis reveals that the covalent bond
between FIIN-2 and a cysteine, uniquely present in the glycine-rich loop
of FGFR kinases, facilitates the DFG-out conformation, which together
with the internal ﬂexibility of FIIN-2 enables FIIN-2 to avoid the steric
clash with the gate-keeper mutation that causes the ponatinib resistance.
The structural data provide a blueprint for the development of next
generation anticancer inhibitors through combining the salient inhibitory mechanisms of ponatinib and FIIN-2.
The FGF family of ligands consists of 18 structurally relatedpolypeptides that signal in paracrine or endocrine fashion
through four FGFRs (FGFR1-FGFR4) and their alternatively
spliced isoforms to regulate a myriad of biological processes in
human development, metabolism, and tissue homeostasis.1,2
FGFs bind and dimerize the extracellular domains of FGFRs in
concert with heparan sulfate glycosaminoglycans or single-pass
Klotho coreceptor proteins positioning the cytoplasmic kinase
domains in proper proximity/orientation for transphosphor-
ylation on A-loop tyrosines.3,4 This event elevates the intrinsic
kinase activity of FGFRs leading to subsequent autophosphor-
ylation on tyrosines in the ﬂanking juxtamembrane (JM) and
C-tail regions that mediate recruitment and phosphorylation of
a distinct set of intracellular eﬀector proteins by the activated
FGFR evoking activation of intracellular signaling pathways.4−6
Uncontrolled activation of FGF signaling due to gain-of-
function mutations in FGFRs, FGFR gene fusions involving
various dimerizing partners, or overexpression/misexpression of
FGFs and FGFRs contributes to a number of developmental
disorders and cancer.7−11 Gain-of-function mutations in FGFRs
were initially discovered in human congenital craniosynostosis
and dwarﬁsm syndromes. Later studies showed that the very
same mutations occur somatically in diverse cancers, including
multiple myeloma,12 bladder cancer,13 endometrial cancer,14
glioblastoma,15 lung cancer,16 adenoid cystic carcinoma,17 and
benign skin cancer.18 FGFR gene fusions, originally found in
the 8p11 myeloproliferative syndrome (an aggressive atypical
stem cell myeloproliferative disorder),7,19 have since been
extended to glioblastoma, bladder, and lung cancers.20,21
Overexpression of FGFs and FGFRs has been documented in
breast, prostate, and bladder cancers.22 Single nucleotide
polymorphism in FGFR2 has been linked with susceptibility
to breast cancer,23 and SNP in FGFR4 has been associated with
resistance to chemotherapy.24 In light of these data, FGFRs are
now considered major targets for cancer drug discovery.
Indeed, several small molecule ATP-competitive inhibitors
are being pursued in the clinic for FGFR-associated cancers
including endometrial and prostate cancer. These include
dovitinib,25 ponatinib,26,27 brivanib,28 multitargeted RTK
inhibitors with coverage of FGFRs, and AZD4547,29 which
has a more restricted FGFR target speciﬁcity proﬁle. In
addition, there are historical FGFR inhibitors such as
PD173074,30 SU5402,31 and FIIN-132 which have been
extensively used as pharmacological probes. All of these
inhibitors are reversible ATP-competitive inhibitors with the
exception of FIIN-1, which covalently targets an unusual
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cysteine located in the glycine-rich loop of FGFR1−4. These
inhibitors exhibit diﬀerential activity proﬁles with most acting
primarily on the autoinhibited FGFRKs, while others also show
activity against FGFR kinases carrying gain-of-function
mutations. However, these inhibitors are ineﬀective against
gate-keeper mutations,33,34 a mechanism that has been well
documented to confer resistance in the clinic to many drugs
targeting oncogenic kinases such as Bcr-Abl (T315I), EGFR
(T790M), PDGFR (T674I), and c-Kit (T670I).
There is a major impetus to elucidate the structure−function
relationships of FGFR kinases including the mechanisms of
action of gain-of-function mutations and inhibitors as such data
can provide crucial information to guide the development of
inhibitors with improved selectivity and potency toward FGFR
isoforms. To date, crystal structures of FGFR1−3 kinases in an
autoinhibited state or in an activated state induced either by A-
loop phosphorylation or by gain-of-function mutations have
been determined.35−37 In addition, for FGFR1 and FGFR2
kinases, crystal structures exist of inhibitor bound forms.38−40
These structural data have guided the discovery of inhibitors
with narrowed speciﬁcity toward FGFR kinases. Notably, the
FGFR1K−PD173074 structure40 was used as template to
develop FIIN-132 and FIIN-2, pyridopyrimidine-based irrever-
sible inhibitors that exhibit greater speciﬁcity toward FGFRs.
These inhibitors carry a reactive acrylamide group that is
capable of forming a covalent bond with the thiol group of a
cysteine uniquely present in the glycine-rich loop of FGFRs.
Importantly, FIIN-2 shows activity against the FGFR kinase
harboring gate-keeper mutation.
Rhabdomyosarcoma is the most common soft tissue sarcoma
in children.8 FGFR4 activation due to overexpression or gain-
of-function mutations in the FGFR4 kinase domain has been
correlated with advanced-stage cancer and poor survival.8,41
FGFR4 inhibition has been shown to stop growth of
rhabomyosarcoma cell lines and cause tumor shrinkage in
xenograft studies,42,43 supporting the notion that these
mutations play causal roles in tumorigenesis. To facilitate the
ongoing drug discovery for rhabdomyosarcoma, we solved the
ﬁrst crystal structures of FGFR4K alone and in complex with
ponatinib and FIIN-2. These structures provide the ﬁrst
examples for a DFG-out mode of inhibition of FGFRK by an
ATP-competitive inhibitor. Remarkably, FIIN-2 also binds in
the DFG-out mode despite not conforming to the pharmaco-
phore required for this binding mode.44 In addition, the FIIN-2
gate-keeper mutant complex demonstrates how the internal
rotational ﬂexibility allows this compound to adapt to the
bulkier side chains at the gate-keeper location, thus retaining its
inhibitory activity. These ﬁndings have general implications for
the structure-guided design of inhibitors that can overcome the
gate-keeper mutation in FGFR and likely other kinases.
■ RESULTS
Crystal Structure of Autoinhibited FGFR4 Kinase. As
expected, the FGFR4 kinase domain (FGFR4K) adopts the
canonical bilobate fold of protein kinases with the smaller N-
Figure 1. The crystal structure of wild-type FGFR4 kinase. (A) Ribbon diagram of the wild-type FGFR4K structure. β strands and α helices are
colored cyan and green, respectively. The A-loop, catalytic loop, kinase insert, and kinase hinge are colored magenta, orange, wheat, and yellow,
respectively. (B) Close-up view of the N-lobe showing formation of the catalytically critical salt bridge between K503 and E520. (C) Close-up view
of the molecular brake at the kinase hinge region. (D) Close-up view of the active site of FGFR4KWT and activated FGFR2K (in slate) complexed
with peptide (in yellow sticks) following superimposition of these two structures. Note that bidentate hydrogen bonds between R650 and D612 (the
general base) block the access of substrate tyrosine into the active site of FGFR4K. The side chain of R650 in the FGFR4K structure occupies
roughly the same space as the substrate tyrosine in the FGFR2K−peptide complex structure. In all ﬁgures, side chains of selected residues are shown
as sticks, and atom colorings are as follows: oxygens in red, nitrogens in blue, and coloring of carbons follow the coloring scheme of the speciﬁc
region of the kinase from which they derive. The hydrogen bonds are shown as black dashed lines.
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terminal lobe exhibiting the characteristic twisted ﬁve-stranded
β sheet and the αC helix and the larger C-terminal lobe
consisting of mainly α helices (Figure 1A). Both the A-loop and
the loop connecting αD and αE helices, referred to as the
kinase insert, are fully ordered. The ordering of the A-loop is
due to the intramolecular contacts between the loop and the
rigid body of the C-lobe. By contrast, the observed
conformation of the kinase insert is solely attributable to
favorable crystal lattice contacts. The kinase insert region of
FGFR4K bulges out of the main body of the kinase domain
and, unlike FGFR1−3 kinases, lacks tyrosine autophosphor-
ylation sites (Supporting Information Figure S1A).
The unphosphorylated FGFR4K is in an autoinhibited
catalytically incompetent state, as evidenced by its comparison
with the published crystal structures of unphosphorylated
auoinhibited FGFR1−2 kinases, and activated FGFR1−3
kinases either by A-loop tyrosine phosphorylation or by
pathogenic gain-of-function mutations (Supporting Informa-
tion Figure S2). As in FGFR1−3 kinases, FGFR4K auto-
inhibition is principally governed by a network of inhibitory
hydrogen bonds at the kinase hinge region termed the
molecular brake (Figure 1C). This network, which is mediated
by a triad of residues consisting of Asn-535, Glu-551, and Lys-
627 in FGFR4K, restrains the N-lobe movement toward the C-
lobe that accompanies kinase activation. Reminiscent of the
unphosphorylated FGFR1K structure, an additional constraint
is provided by the DFGLAR motif at the beginning of the A-
loop, whose conformation physically interferes with N-lobe
rotation.36 In fact, as in the unphosphorylated FGFR1K and
FGFR2K structures, FGFR4K also contains the catalytically
important salt bridge between Lys-503 and Glu-520 (αC),
which is known to help orient Lys to coordinate α and β
phosphates of ATP (Figure 1B). Last, as in FGFRK1,36 the
FGFR-invariant Arg-650 at the C-terminal end of the A-loop
makes bidentate hydrogen bonds with Asp-612 (the general
base) from the catalytic loop, thereby directly blocking the
access of substrate into the active site (Figure 1D).
The FGFR4K Gate-Keeper Mutations Confer Resist-
ance to Ponatinib but Are Sensitive to FIIN-2. As alluded
to previously, ponatinib (previously AP24534; Supporting
Information Figure S3A) is a multitargeted RTK inhibitor
with coverage of FGFR kinases that is currently being evaluated
in clinical trials for several cancers including endometrial cancer
and rhabdomyosarcoma.27,45 Importantly, we have recently
shown that, in contrast to other FGFR inhibitors including
dovitinib and PD173074, ponatinib is capable of eﬀectively
targeting not only the autoinhibited FGFR2 kinases but also
FGFR2K that has undergone activation by gain-of-function
mutations with the exception of gate-keeper mutation.33 Using
the FGFR1K−PD173074 complex structure as a template, we
have recently developed an irreversible covalently acting
inhibitor, termed FIIN-2 (Supporting Information Figure
S3B), that is capable of targeting FGFRKs harboring gate-
keeper mutations.
To date, four oncogenic FGFR4 mutations have been
identiﬁed in rhabdomyosarcoma tumors including N535K,
N535D, V550L, and V550E.8 According to our structure, the
N535K or N535D mutations confer gain-of-function by
disengaging the autoinhibitory molecular brake at the kinase
hinge region. By contrast, the mechanism by which the V550L
and V550E mutations confer gain-of-function is not fully
understood. These mutations aﬀect the gate-keeper residue of
FGFR4 kinase that is known to control the access of ATP-
competitive inhibitors to the rear hydrophobic pocket in the
ATP binding cleft. We ﬁrst assessed the kinase activities of
oncogenic FGFR4K variants harboring the V550E, V550L,
N535D, or N535K rhabomyosarcoma mutations using an in
vitro peptide phosphorylation assay. Consistent with the
published cell-based data,8 all four mutants exhibited elevated
kinase activity compared to wild-type kinase as evident by the
rapid completion of substrate monophosphorylation and
appearance of diphosphorylated substrate peaks in the mass
spectra of the oncogenic variants (Figure 2).
Next, the abilities of ponatinib and FIIN-2 to inhibit wild-
type FGFR4K and its four oncogenic variants were examined.
The data showed that ponatinib inhibited not only the wild-
type FGFR4K (Figure 3A, left panel) but also FGFR4Ks that
have undergone activation either by A-loop phosphorylation
(Supporting Information Figure S4) or by gain-of-function
mutations (N535K or N535D; Supporting Information Figure
Figure 2. FGFR4K mutants harboring rhabdomyosarcoma mutations exhibiting elevated kinase activity. The substrate phosphorylation activities of
FGFR4KWT, FGF4KN535K, FGFR4KN535D, FGFR4KV550L, and FGFR4KV550E were compared using native-PAGE (upper panel) coupled with time-
resolved MALDI-TOF MS (lower panel). 0P, 1P, and 2P indicate the positions of the unphosphorylated, monophosphorylated, and
dephosphorylated substrate peptide.
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S5). The V555L and V550E gate-keeper mutants were resistant
to inhibition by ponatinib, however (Figure 3A and Supporting
Information Figure S5). By contrast, FIIN-2 eﬀectively
inhibited the substrate phosphorylation ability of all mutants
including the V550L gate-keeper mutant (Figure 3B). To
understand the molecular basis for the diﬀerential sensitivity of
the FGFR4K gate-keeper mutations to ponatinib and FIIN-2,
we decided to determine the crystal structures of wild-type
FGFR4K bound to ponatinib, the FGFR4KV550L gate-keeper
mutant alone, and in complex with FIIN-2.
Ponatinib Inhibits FGFR4K by Inducing a DFG-in →
DFG-out Rearrangement. The FGFR4K−ponatinib complex
crystallized under identical conditions to the free FGFR4K,
yielding crystals that were isomorphous to the free FGFR4K
crystals. As anticipated, ponatinib binds into the ATP binding
pocket between the N and C lobes (Figure 4A). Drug binding
Figure 3. The V550L gate-keeper mutation conferring resistance to ponatinib but not to FIIN-2. The abilities of ponatinib (A) and FIIN-2 (B) to
inhibit substrate phosphorylation activities of FGFR4KWT and the FGFR4KV550L (gate-keeper mutant) were compared using native-PAGE (upper
panel) and time-resolved MALDI-TOF MS (lower panel). 0P, 1P, and 2P indicate the positions of the unphosphorylated, monophosphorylated, and
dephosphorylated substrate peptide. (C) Antiproliferative activity of ponatinib and FIIN-2 on transformed Ba/F3 cells.
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does not induce any signiﬁcant change in the interlobe angle.
The C-alpha atoms of FGFR4K−ponatinib and apo-FGFR4K
structures superimpose very well (RMSD of 0.2 Å) with the
exception of the DFG motif at the beginning of the A-loop,
which undergoes a dramatic DFG-in → DFG-out rearrange-
ment in response to ponatinib binding (Figure 4A and
Supporting Information Figure S6A).
Ponatinib consists of an imidazo[1,2-b]pyridazine hetero-
cyclic scaﬀold that is linked via an acetylene group to a
methylphenyl ring that in turn is joined via an amide bond to a
triﬂuoromethylphenyl aromatic ring (Figure 4A). A methyl-
piperazine ring has been appended via methyl linkage to the
triﬂuoromethylphenyl aromatic ring to aid in penetration of the
drug into cells. Ponatinib binds into the ATP binding cleft in an
extended conformation. The methylphenyl and triﬂuorome-
thylphenyl rings are almost coplanar and have a 90° interplanar
angle with the (imidazo[1,2-b]pyridazine) bicyclic aromatic
ring. Ponatinib engages a vast area that stretches from the
kinase hinge region at the back of the kinase all the way to the
catalytic pocket at the front end of the kinase.
The aromatic rings of the drug engage three sites within the
ATP binding cleft (Figure 4A). At site 1, the imidazo[1,2-
b]pyridazine scaﬀold occupies approximately the same space as
the adenine ring of ATP and makes a single hydrogen bond
with the backbone amide nitrogen atom of Ala-553 in the
kinase hinge region (Figure 4A, middle panel). Reminiscent of
ATP binding, the imidazo[1,2-b]pyridazine aromatic ring is
sandwiched between hydrophobic residues from N- and C-
lobes of the kinase. The rigid acetylene linkage directs the
remaining portion of the drug deep toward the rear corner of
the ATP binding pocket where the methylphenyl and 3-
triﬂuoromethylphenyl aromatic rings of the inhibitor engage
sites 2 and 3, respectively (Figure 4A, middle panel).
Importantly, these aromatic rings induce two signiﬁcant
conformational changes in the ATP binding cleft including
(I) displacement of the catalytic Lys-503 side chain in site 2 and
(II) an outward ﬂipping of the DFG motif in site 3 (Figure 4A,
right panel). These structural rearrangements are necessary to
alleviate steric conﬂicts with the compound ultimately
optimizing binding interactions of the inhibitor.
At site 2, the methylphenyl group pushes the side chain of
catalytic Lys-503, which along with Val-550, the gate-keeper
residue, and Met-524 from the αC helix form a hydrophobic
pocket that binds the methylphenyl aromatic ring. The
displacement of Lys-503 indirectly helps the catalytic Glu-520
from the αC helix to make a direct hydrogen bond with the
amide linkage between aromatic rings of the drug (Figure 4A,
middle panel). At site 3, the 3-triﬂuoromethylphenyl moiety
expels the DFG phenylalanine out of the cleft and occupies the
hydrophobic pit that becomes vacant upon outward movement
of the phenylalanine (Figure 4A, right panel). The displaced
phenylalanine side chain is now in position to engage in
Figure 4. Structural basis for FGFR4KWT inhibition by ponatinib and resistance caused by the V550L gate-keeper mutation. (A) Ribbon diagram of
the FGFR4KWT−ponatinib cocrystal structure. The middle panel shows the close-up view of the main interactions between FGFR4KWT and
ponatinib. The hydrogen bonds are indicated as black dashed lines, and the hydrophobic interactions are shown as surface. The right panel shows a
close-up view of the DFG motif in the FGFR4KWT (in orange) and FGFR4KWT−ponatinib (in cyan) following superimposition of the two
structures. Note that ponatinib forces the DFG out of the ATP binding pocket. The phenylalaninein DFG region and K503 are rendered as orange
and cyan sticks and labeled in black and cyan, respectively. (B) Ribbon diagrams of the FGFR4KV550L structure. Superimposition of the FGFR4KWT−
ponatinib complex structure onto FGFR4KV550L reveals steric clashes between the added methyl group in Leu-550 and the imidazo[1,2-b]pyridazine
scaﬀold of ponatinib which underlie the resistance of the FGFR4KV550L to ponatinib. The V550 in FGFR4KWT and L550 in FGFR4KV550L are shown
in pink and yellow sticks, and labeled in pink and red, respectively. In all the structures, the ponatinib is rendered as sticks and labeled in black.
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favorable hydrophobic contacts with the scaﬀold and the
acetylene linker (Figure 4A, middle panel). As another
important consequence of phenylalanine displacement, Asp-
630 from DFG is also forced into a catalytically incompetent
orientation where the backbone atoms of Asp-630 gain the
ability to make hydrogen bonds with the amide linkage between
the aromatic rings of the inhibitor. Interestingly, even the
piperazine moiety of the drug contributes to drug binding
aﬃnity. The piperazine ring falls in the vicinity of the catalytic
loop where it engages in hydrogen bonds with the loop (Figure
4A, middle panel). The overall binding mode of ponatinib in
the FGFR4K−ponatinib structure resembles that observed in
the Abl−Ponatinib complex structure where the DFG-out
mode of inhibition was initially observed.46 Unlike Abl−
Ponatinib, however, the glycine-rich loop of FGFR4 does not
partake in ponatinib recognition.
Gate-Keeper Mutations Confer Resistance to Ponati-
nib Inhibition by Introducing a Steric Clash with the
Inhibitor. As shown in Supporting Information Figure S5,
ponatinib is capable of silencing all the FGFR4 pathogenic
mutations with the exception of the V550L and V550E gate-
keeper mutations. To understand the molecular basis for how
these mutations render the kinase refractory to inhibition, we
also solved the crystal structure of FGFR4K harboring the
V550L gate-keeper mutation (Figure 4B). Superimposition of
the FGFR4K−ponatinib complex structure onto FGFR4KV550L
reveals steric clashes between the added methyl group in Leu-
550 and the imidazo[1,2-b]pyridazine scaﬀold of ponatinib
Figure 5. Structural basis for the inhibition of FGFR4KV550L gate-keeper mutant by FIIN-2. (A) The chemical structure of FIIN-2. (B) The LC-MS/
MS spectra of the kinase peptide (Pro42-Arg53) from FGFR4KWT and FGFR4KV550L with and without FIIN-2. The reacting Cys477 from the
glycine-rich loop of the kinase is highlighted in red color. (C) Ribbon diagram of the FGFR4KV550L−FIIN-2 cocrystal structure. (D) The close-up
view of the main interactions between FGFR4KV550L and FIIN-2. The hydrogen bonds are indicated as black dashed lines, and the hydrophobic
interactions are shown as surface. (E) Close-up view of the DFG motif conformation in the FGFR4KWT (in orange), FGFR4KV550L (in teal), and
FGFR4KV550L−FIIN-2 (in blue) structures following superimposition of the three structures. Note that FIIN-2 also binds to the ATP-binding site of
FGFR4K in DFG-out mode. The phenylalanines in the DFG region of FGFR4KWT, FGFR4KV550L, and the FGFR4KV550L−FIIN-2 complex are
rendered as orange, teal, and blue sticks and labeled in black and blue, respectively. (F) Superimposition of the FGFR4KWT−FIIN-2 complex
structure onto the FGFR4KV550L−FIIN-2 structure. Note that rotational freedom around the single bond linking the scaﬀold and dimethoxyphenyl of
FIIN-2 allows for small structural adjustments to bypass any potential steric clash with the bulkier side chain of L550. The V550 in FGFR4KWT and
L550 in FGFR4KV550L are shown in orange and yellow sticks, and labeled in orange and red, respectively. (G) The distances between L550 of the
FGFR4KV550L gate-keeper mutant and FIIN-2 are shown as dashed lines and labeled in a black color. In all of the structures, the FIIN-2 is rendered
as sticks and labeled in black.
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which underlie the resistance of the FGFR4KV550L to ponatinib
(Figure 4B).
Crystal Structure of FGFR4KV550L Complexed with
FIIN-2. As shown in Figure 3, unlike ponatinib, FIIN-2 is
capable of inhibiting the gate-keeper V550L mutant. To
understand how FIIN-2 is capable of overcoming gate-keeper
mutations, the crystal structure of the FGFR4KV550L mutant in
complex with FIIN-2 was solved. FIIN-2 is a PD173074-based
compound in which the cyclic urea N of the pyridopyrimidine
scaﬀold has been derivatized with an acrylamidobenzyl
substituent possessing a reactive acrylamide in the para position
(Figure 5A and Supporting Information Figure S3B). The
benzyl moiety serves as a spacer to position the acrylamide, the
electrophilic center of the compound in the vicinity of the thiol
group of a unique cysteine in the glycine-rich loop of FGFRs
(Supporting Information Figure S1C) allowing for formation a
covalent bond via a Michael addition reaction. To this end, we
ﬁrst used mass spectrometry to demonstrate that FIIN-2
irreversibly reacts with Cys-477 (in the glycine-rich loop) in
both FGFR4KWT and FGFR4KV550L. To do so, FGFR4KWT and
FGFR4KV550L were incubated with FIIN-2 and digested with
trypsin, and adduct formation between the tryptic peptide
containing Cys-477 and FIIN-2 was analyzed by tandem mass
spectrometry. As shown in Figure 5B, in the presence of FIIN-
2, the mass of the tryptic peptide containing the Cys-477
increased by 634.3 Da, corresponding to the mass of the drug,
conﬁrming that FIIN-2 can irreversibly inhibit both FGFR4KWT
and FGFR4KV550L.
The FGFR4KV550L−FIIN-2 complex structure shows that like
ponatinib, FIIN-2 binding does not aﬀect the kinase interlobe
angle (Figure 5C and Supporting Information Figure S7A).
The C-alpha atoms of FGFR4KV550L−FIIN-2 and apo-
FGFR4KV550L match closely with the exceptions of the
glycine-rich loop and the DFG motif, both of which undergo
major conformational rearrangements in response to drug
binding (Figure 5C,D,E and Supporting Information Figure
S7B). Remarkably, the DFG motif undergoes an outward
transition reminiscent of that seen in the FGFR4K−ponatinib
structure (Figure 5E). This is rather surprising because FIIN-2,
like its parent molecule PD173074, lacks a functional group
necessary to actively force the DFG out of the ATP binding
cleft. As detailed below, this unusual property of FIIN-2, a type-
I inhibitor, to bind FGFR4K like a type-II inhibitor is a direct
consequence of the covalent bonding between FIIN-2 to
FGFR4K.
The pyridopyrimidine scaﬀold of FIIN-2 occupies roughly
the same space as the bicyclic ring of ponatinib (site 1) and is
sandwiched by hydrophobic residues from the N and C lobes of
kinase (Figure 5C,D). Likewise, the dimethoxyphenyl ring, the
key determinant of selectivity of PD173074 and likewise FIIN-2
for FGFRs, penetrates deep into the back pocket of the cleft
engaging the same site as the methylphenyl ring of ponatinib
(site 2). The acrylamidobenzyl group protrudes out of the
ATP-binding pocket and places its a,b-unsaturated acrylamide,
the electrophilic center of the drug, in the vicinity of
nucleophilic thiol group of Cys-477, resulting in a covalent
bond formation via a Michael addition reaction (Figure 5). This
covalent bonding pulls the glycine-rich loop toward the
compound enabling additional contacts between the compound
and the glycine-rich loop to form. Speciﬁcally, the phenyl-
alanine from the glycine-rich loop makes hydrophobic contacts
with the acrylamidobenzyl ring of drug and backbone amid
nitrogens of the glycine-rich loop form a hydrogen bond with
the carbonyl group of acrylamide of the drug (Figure 5D). In
addition to causing the observed conformational change of the
glycine-rich loop, the covalent bond between FIIN-2 and the
glycine-rich loop cysteine is ultimately responsible for the
DFG-ﬂip seen in the structure. Speciﬁcally, the altered
conformation of the glycine-rich loop creates favorable p−p
stacking contacts between the Phe-478 from the glycine-rich
loop and the Phe-631 from the DFG motif (Figure 5D), which
stabilizes the DFG-out conformation enabling the Phe-631 to
also contribute to inhibitor binding.
Comparison of the FGFR4KV550L−FIIN-2 and FGFR4KWT−
ponatinib structures explains the molecular basis for the
diﬀerential sensitivity of these two inhibitors toward the
V550L gate-keeper mutation. While the added methyl group
in Leu-550 introduces steric clash with the imidazo[1,2-
b]pyridazine scaﬀold of ponatinib (Figure 4B, right panel),
Leu-550 is still able to make favorable hydrophobic contacts
with the dimethoxyphenyl ring of FIIN-2 (Figure 5D). It is
noteworthy that the rigidity of the acetylene linkage is
disadvantageous as it precludes any structural adjustment of
the methylphenyl moiety of ponatinib (Supporting Information
Figure S3A) to alleviate this steric clash. In contrast, rotational
freedom around the single bond linking the scaﬀold and
dimethoxyphenyl of FIIN-2 (Supporting Information Figure
S3B) would allow for small structural adjustments to bypass
any potential steric clash with the bulkier side chain of L550.
Indeed, an overlay of the crystal structure of the FGFR4KWT−
FIIN-2 complex onto the FGFR4KV550L−FIIN-2 structure
shows that the dimethoxyphenyl ring in the FGFR4KV550L−
FIIN-2 complex undergoes slight rotation around the single
bound linker to accommodate for the bulkier leucine side chain
in the gate-keeper mutant (Figure 5F,G).
■ DISCUSSION
In this report, we elucidated the molecular bases for FGFR4
kinase autoinhibition, inhibition by ponatinib and FIIN-2, and
drug resistance caused by gate-keeper mutations. The
FGFR4K−ponatinib and FGFR4K−FIIN-2, reported here, are
the ﬁrst examples of FGFR−inhibitor complexes featuring a
DFG-out mode of inhibition. In fact, only a tiny fraction of
published tyrosine kinase-inhibitor structures depict a DFG-out
mode of inhibition. Among RTKs, KIT, TIE2, MET, and
VEGFR2 are the only examples that have been shown so far to
bind inhibitors in a DFG-out fashion.47−49
Previously, crystal structures of FGFR1 and FGFR2 kinases
in complex with inhibitors bearing oxyindole and pyridopyr-
imidine and quinazolin as scaﬀolds have been solved.38,39,50 In
none of these structures, however, does the inhibitor penetrate
deep enough to access site 3, and accordingly the DFG motif
remains in its original “in” conformation. In fact, the oxyindoles
do not even make use of site 2, although they can induce
conformational changes in the glycine-rich loop to create
hydrophobic contacts between conserved phenylalanine from
the glycine-rich loop and the drug contributing to drug aﬃnity.
The FGFR4K−ponatinib (Figure 4) and FGFR4K−FIIN-2
(Figure 5) complex structures elegantly demonstrate that these
two inhibitors attain their superior inhibitory potency against
FGFR kinases by binding the kinase via a DFG-out mechanism.
In addition, the FGFR4K−FIIN-2 structure, the ﬁrst structure
of an FGFR kinase with a covalently acting inhibitor (Figure 5),
shows how this compound takes advantage of a unique cysteine
in the glycine-rich loop of FGFRs to achieve FGFR target
speciﬁcity.
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Interestingly, in contrast to FGFRs, where the DFG-out
conformation has never been visualized in the previously
published apo crystal structures, there are structures of
unliganded KIT and Abl that display a DFG-out conformation
in the absence of an inhibitor.51,52 These data imply that in
FGFRs, the DFG motif rarely transitions into the out
conformation, whereas the DFG-out conformation can occur
with signiﬁcant frequencies in these other RTKs. Since the
relative distribution of the DFG-in/DFG-out states will dictate
the energetics of drug binding, future eﬀorts should be directed
toward exploring the dynamics of this transition in solution.
Taken together, comparison of FGFR4K−ponatinib and
FGFR4K−FIIN-2 complex structures with previous FGFRK−
inhibitor complexes showcases a substantial degree of
conformational heterogeneity both in the DFG motif and
glycine-rich loop that should be harnessed when tailoring more
eﬃcacious FGFRK inhibitors. The structural data provide
roadmaps for the design of novel inhibitors for FGFRKs which
incorporate the salient inhibitory features of ponatinib and
FIIN-2. In the FGFR4K−FIIN-2 structure, the hydrophobic
pocket (site 3) that becomes vacant upon outward ﬂipping of
the DFG phenylalanine remains unutilized. Hence, the
inhibitory potency of FIIN-2 may be signiﬁcantly improved
by derivatizing it with an aromatic ring such that it gains the
ability to engage this hydrophobic pocket as it occurs in the
FGFR4K−ponatinib structure. Likewise, the structural data
pinpoint two unique cysteines, one in the catalytic loop of all
four FGFRKs35 and the other in the hinge region of FGFR4K
(Supporting Information Figure 1B) that can be exploited for
the design of more selective covalent inhibitors for FGFR4K
and other FGFRs.
■ METHODS
Please refer to the Supporting Information for full details.
Protein Expression and Puriﬁcation. The human FGFR4 kinase
domains FGFR3K445−753, including its mutated forms, and the C-
terminal tail peptide of FGFR2 kinase (FGFR2K761−821) were all
expressed using pET bacterial expression vectors with an N-terminal
6XHis-tag to aid in protein puriﬁcation.
Crystallization and Structure Determination. All the crystals
were grown by hanging drop vapor diﬀusion method either at 4 °C
(FGFR4KWT, FGFR4KV550L, and FGFR4KWT−ponatinib) or 18 °C
(FGFR4KV550L/Cys477−FIIN-2). FGFR4KWT crystallized in a buﬀer
composed of 0.1 M MES (pH 5.5), 20% (w/v) PEG 4000, 0.2 M
Li2SO4, and 0.01 M taurine. Crystals of the FGFR4K
V550L were
obtained using a crystallization buﬀer composed of 0.1 M Tris (pH
7.5), 20% (w/v) PEG 1500, and 0.2 M (NH4)2SO4. The FGFR4K
WT−
ponatinib complex was crystallized using a crystallization buﬀer
composed of 0.1 M MES (pH 5.5), 25% (w/v) PEG 4000, 0.15 M
(NH4)2SO4, and 4% (v/v) formamide. The FGFR4K
V550L/C477−FIIN-
2 complex was crystallized using a crystallization buﬀer composed of
0.1 M HEPES (pH 7.5), 1.0−1.2 M (NH4)2SO4, and 10 mM
yttrium(III) chloride hexahydrate. All diﬀraction data were processed
using the HKL2000 suite,53 and the crystal structures were solved
using maximum likelihood molecular replacement program Phaser in
the PHENIX software suite.54 The crystal structure of wild-type
FGFR2 kinase (PDB ID: 2PSQ)35 was used as the search model.
Model building was carried out using Coot,55 and reﬁnements were
done using phenix.ref ine in the PHENIX suite.54 Data collection and
structure reﬁnement statistics are listed in Table 1.
Peptide Substrate Phosphorylation Assay by Native Gel and
MALDI-TOF Mass Spectrometry. Peptide substrate phosphoryla-
tion activities of wild-type and pathogenic mutated FGFR4 kinases
(FGFR4KWT, FGFR4KN535 K, FGFR4KN535D, FGFR4KV550L,
FGFR4KV550E) and the inhibitory eﬃciency of ponatinib or FIIN-2
were analyzed by native gel electrophoresis and positive ion MALDI-
TOF MS (Bruker Autoﬂex MALDI-TOF, Bruker Daltonics) in linear
mode.
Table 1. X-ray Data Collection and Reﬁnement Statistics
construct FGFR4Kapo FGFR4K-Ponatinib FGFR4KV550L FGFR4KV550L-FIIN-2
data collection
resolution (Å) 50.0−1.50 (1.53−1.50) 50−1.90 (1.93−1.90) 50−1.68 (1.71−1.68) 50−2.2 (2.24−2.20)
space group P21 P21 P21 R3
unit cell parameters (Å, deg) a = 42.384 a = 42.722 a = 42.671 a = 139.599
b = 61.336 b = 61.593 b = 61.472 b = 139.599
c = 61.084 c =60.311 c = 61.819 c = 49.660
α = 90.00 α = 90.00 α = 90.00 α = 90.00
β = 99.01 β = 97.94 β = 99.43 β = 90.00
γ = 90.00 γ = 90.00 γ = 90.00 γ = 120.00
content of the asymmetric unit 1 1 1 1
measured reﬂections (#) 348260 182746 243115 88774
unique reﬂections (#) 49375 24319 34654 18138
data redundancy 7.1 (6.0) 7.5 (7.7) 7.0 (5.4) 4.9 (2.4)
data completeness (%) 100 (100) 99.2 (98.1) 96.6 (94.2) 99.1 (90.1)
Rsym (%) 5.8 (19.5) 7.5 (30.3) 5.2 (16.7) 10.2 (34.4)
I/sig 53.6 (8.6) 41.8 (7.4) 50.2 (10.0) 13.5 (1.7)
reﬁnement
R factor/R free 22.2/24.8 17.8/21.2 23.5/26.9 19.3/23.4
number of protein atoms 2204 2317 2242 2139
number of nonprotein/solvent atoms 10 44 5 47
number of solvent atoms 0 49 0 0
RMSD bond length (Å) 0.005 0.015 0.006 0.008
RMSD bond angle (deg) 1.04 1.61 1.00 1.23
PDB ID 4QQT 4QRC 4QQJ 4QQ5
aNumbers in parentheses refer to the highest resolution shell. bRsym = Σ|I − I|ΣI, where I is the observed intensity of a reﬂection, and I is the average
intensity of all the symmetry related reﬂections.
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Inhibition of Kinase Autophosphorylation by Ponatinib. The
autophosphorylation of the wild-type FGFR4 kinase and its
pathogenic variants (FGFR4KWT, FGFR4KN535K, FGFR4KN535D,
FGFR4KV550L, FGFR4KV550E) inhibited by ponatinib were analyzed
by native gel electrophoresis and LTQ Orbitrap (Thermo Electron)
LC-MS/MS.
BaF3 Cell Viability Assay. TEL-FGFR4-transformed BaF3 cells
were seeded in a 96 well plate and treated with the indicated
concentration of the compounds. After 72 h, cell viability was assessed
by MTS assay. The IC50 values were calculated using GraphPad Prism
version 5.0 (GraphPad Software Inc.). To generate the FGFR4V550L
expressing BaF3 cell line, the V550L mutation was introduced into the
Tel-FGFR4WT chimera, which had been subcloned into the retroviral
expression vector, using site-directed mutagenesis (Agilent) and was
tranduced into BaF3 cell line using retroviral infection.
Analysis of Covalent Bond Formation between FIIN-2 and
FGFR4K by LC-MS/MS. To test if FIIN-2 can form a covalent bond
with Cys477 in the glycine-rich loops, FGFR4KWT/C477 and
FGFR4KV550L/C477 were incubated with FIIN-2 overnight at 4 °C,
digested with trypsin, and analyzed by LC-MS/MS. The spectral
region corresponding to the kinase tryptic peptide (Pro42−Arg53),
which contains the reactive Cys477, was extracted from the raw data
and was used to show the mass shift of the peptide in the presence of
FIIN-2.
The coordinates and structure factors have been deposited in the
RCSB Protein Data Bank under PDB IDs 4QQT, 4QRC, 4QQJ, and
4QQ5 and will be immediately released upon publication.
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